Replies to post #121756 on Biotech Values

[mcbio]

It was a loser back when they failed their trial back in '09?, or '10?

LOL BTH, you really do crack me up. Have you forgotten that failure is the norm in biotech, not the exception? Most drugs fail at some point.

I got back involved because I looked at their pipeline and clearly one would think that many drugs would be worth more than $130 mill market cap considering some reallll pig trash-heaps (SNSS et al) have market caps comparable or even more than ARRY's current.

So if you still believe all of this, why would you be so down on the stock? Please tell me where the fundamentals have changed in the story. Has MEK lost its potential in oncology? Has AZN or NVS/ARRY presented some negative data that I missed?

If the upcoming MEK data is negative or otherwise uninspiring in these initial two indications, then clearly ARRY will likely drop even further. But, if there's any positive sign, I'd like to think there's the potential for some good upside here.

If ARRY dips below $2, I may consider adding again.